Lasa Supergenerics Q1 FY27 results on 14 Aug 2026

What the company told exchanges

Lasa Supergenerics Ltd (BSE: 540702, NSE: LASA) has informed the BSE that its Board of Directors will meet on Friday, August 14, 2026. The primary agenda is to consider, approve and take on record the company’s unaudited financial results for the quarter ended June 30, 2026, which corresponds to Q1 FY27. The intimation is made under the disclosure framework typically used for board meetings where quarterly numbers are approved. The company also stated that any other matter may be discussed with the permission of the Chairperson. The exchange communication references a company filing identifier: LASA/SE/26-27/13. The disclosure also notes that the intimation is available on the company website and on the BSE and NSE websites.

Board meeting agenda: Q1 FY27 unaudited financials

The scheduled meeting is focused on quarterly financial reporting rather than a corporate action such as a dividend, split, or fundraising. The language of the agenda is specific: the board will consider and approve unaudited financial results for the quarter ended June 30, 2026. The disclosure does not provide any preliminary numbers, management commentary, or guidance. It also does not quantify a financial impact from the meeting itself. Investors typically track such meeting dates because they indicate when results may be released to the market. The company has described the results as “unaudited”, which is standard for quarterly reporting accompanied by a limited review from auditors in many cases.

Trading window closure under SEBI insider trading rules

Alongside the meeting intimation, Lasa Supergenerics has stated that the trading window will remain closed. The closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company’s internal code of conduct. As per the disclosure, the trading window will be closed until 48 hours after the declaration of the unaudited financial results. The closure is specifically linked to the Q1 FY27 results declaration. Such closures apply to designated persons and insiders as defined by the company’s policy. The exchange note does not specify the exact start date of the closure, only the condition for reopening.

What is known about the timing of earnings

The data provided also mentions: “Earnings: Expected on 14/08/2026.” This aligns with the board meeting date disclosed for approval of Q1 FY27 numbers. In many cases, companies approve and publish results the same day as the board meeting. However, the disclosure does not explicitly state the publication time. It only confirms the meeting schedule and the agenda. Investors tracking the stock around the date may therefore watch for the outcome announcement filed after the meeting.

Recent price snapshots cited in the data

The information set includes multiple price snapshots from different timestamps. One snapshot (Aug 05, 14:52) shows a price of ₹7.59, up ₹0.58 (8.27%). Another nearby entry shows ₹7.54, up ₹0.43 (6.05%). Separately, it states that “as of Today at 21:44 UTC, shares in Lasa Supergenerics are trading at IN₹7.13.” It also lists: Open ₹7.22 and Previous Close ₹7.52, and states “The current price of Lasa Supergenerics Ltd is ₹7.62.” Because these values correspond to different moments, they should be read as point-in-time references rather than a single continuous quote.

Key facts table

Background: Q1 FY26 and Q3 FY26 results referenced

The dataset also contains earlier quarterly performance references that help frame why the upcoming Q1 FY27 print may be watched. For Q1 FY26, the company’s revenue is cited as ₹201.5 million, down 35% from 1Q 2025. Net loss for the same quarter is shown as ₹211.2 million, and the loss per share is stated at ₹4.22, worsening from a ₹0.55 loss per share in 1Q 2025. Separately, a line on Q1 FY26 also lists “Revenue from Operations for Q1 FY26: ₹2,001.18 lakhs,” which equals ₹200.118 million, consistent with the ₹201.5 million figure in the same information pack.

For Q3 FY26, the material states the company reported a net loss of ₹255.47 lakhs, which equals ₹25.547 million. It compares this with a net profit of ₹549.39 lakhs, or ₹54.939 million, in the same quarter last year. The note attributes the quarter to a period “amid production halt,” but does not provide additional operational details in the text provided. It also references a board meeting scheduled for February 13, 2026 to review unaudited financial results for Q3 FY2026 (quarter ended December 31, 2025), and notes a similar 48-hour trading window reopening rule.

Quarterly snapshot from the provided table (normalised)

The dataset includes a quarterly table titled “Quarterly Results of Lasa Supergenerics (in Rs. Cr.)” for five quarters. Below is a normalised view converted into INR million (₹m), where ₹1 crore equals ₹10 million.

Longer-term revenue trend cited (FY22 to FY26)

A separate “Financial Summary” table in the data lists total revenue (unit explicitly stated as IN₹m) for year-ends 31 March across FY22 to FY26. It shows total revenue of ₹1,371.27 million (FY22), ₹1,295.68 million (FY23), ₹1,043.35 million (FY24), ₹1,424.48 million (FY25), and ₹251.41 million (FY26). The same table mentions a CAGR/average of -34.11%. The dataset does not provide accompanying notes for the sharp change shown for FY26, so the numbers should be read as presented in the source table. No forward estimates are provided beyond “n/a” entries for FY27E and FY28E.

Company identifiers and contact details in the disclosure pack

The information includes a registered address at Plot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Tal: Khed, Ratnagiri Dist., Maharashtra 415722, along with telephone numbers 02145-232101 and 02145-232202, and an investor email: investor@lasalabs.com. It also lists the company website as http://www.lasalabs.com (also shown as https://lasalabs.com/ in another line). Another address line appears as “B/207, CITI Point, Andheri, MUMBAI, 415722” and names a contact “Mitti Jain,” alongside phone +91 2145232101. The dataset does not clarify whether these represent different offices or a reporting artefact, so readers should treat them as contact references included in the provided material.

Market impact: what the disclosure does and does not say

From a market-disclosure standpoint, the most actionable detail is the confirmation of the result-approval meeting date and the trading window closure condition. The company explicitly states that the financial impact is not quantified in the disclosure and that the meeting is for review and approval of quarterly results. That means there is no official indication in this filing about revenue, profit, exceptional items, operational disruptions, or recovery status for the June 2026 quarter. Any market reaction around the date typically depends on the actual results once filed with exchanges.

The dataset also states: “The market capitalization of Lasa Supergenerics Ltd is currently ₹38.18.” The unit is not specified in the text provided, so it should be interpreted strictly as a displayed figure rather than a confirmed crore or million value.

Why the 14 August date matters for investors

Board meeting schedules are closely tracked because they anchor the results calendar and set expectations for disclosures. In Lasa Supergenerics’ case, the same data pack also contains recent loss-making quarters and a sharp swing in profitability across periods, which can increase attention on upcoming numbers. The trading window rule also signals that the company is treating the period as price-sensitive until the results are publicly available. The next confirmed step from the company is the board meeting on August 14, 2026, after which the unaudited Q1 FY27 financial results are expected to be declared and filed with exchanges.